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Polymyositis as a Rare Musculoskeletal Manifestation of 
Chronic Graft-Versus-Host Disease: A Case Report of a 33-Year-
Old Patient 
David Ben-Nun.1 
Abstract 
Background: Musculoskeletal manifestations of chronic Graft-Versus-Host Disease (GVHD) are rare and unfamiliar to most clinicians. Here we discuss the 
pathophysiology of chronic GVHD, current treatments and direction of research for improved therapy and prophylaxis and focus on the common and less 
common musculoskeletal complications of this unfortunately prevalent and burdensome disease. The Case: This is a case report of a 33-year-old male 
with a past medical history of Acute Myeloid Leukemia (AML) who presented with a 1-month history of generalized, proximal weakness and was found to 
have polymyositis secondary to chronic GVHD. Elicitation of further history showed that the patient had had multiple manifestations of both acute and 
chronic graft-versus-host disease in the two years following hematopoietic stem cell transplantation (HSCT). Conclusion: It is important for clinicians to be 
familiar with polymyositis secondary to chronic GHVD, which may appear in patients more than 100 days following allogenic HSCT and typically presents 
as diffuse, generalized myopathy with preserved sensation and elevated CPK and aldolase. The current mainstay of treatment is glucocorticoids with or 
without a calcineurin inhibitor, however due to the side effects associated with long term treatment, more effective prophylactic and therapeutic treatments 
are needed to address this and other manifestations of chronic GVHD. 
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Introduction 
Graft-Versus-Host Disease (GVHD) is a pathological process that occurs 
when immune cells from a donor graft recognize host antigens as 
foreign and trigger an immune response. GVHD is the most common 
life-threatening complication of allogenic hematopoietic stem cell 
transplantation (HSCT) and is classified into acute and chronic based 
on the length of time after which the immune response occurs following 
transplantation.1 Acute GVHD is considered any manifestation of graft T 
cell immune activation within the first 100 days following HSCT.2 Typical 
signs and symptoms of acute GVHD include a maculopapular rash, 
hyperbilirubinemia with jaundice, nausea and vomiting, anorexia, and 
watery or bloody diarrhea with crampy abdominal pain.3 By some 
estimates, incidence of acute GVHD may be as low as 9% or up to 50% 
of patients who undergo HSCT from Human Leukocyte Antigen (HLA)-
matched sibling donors, which indicates that it is a significant medical 
problem especially given the fact that HSCT is a relatively common 
procedure.4–6 Between the years 2013-2017, the Center for International 
Blood and Marrow Transplant Research reported that 106,112 HSCT 
procedures were carried out in the United States. Out of that total, 
approximately 43,962 were allogeneic transplants, which is an average 
of 8,792 allogeneic HSCTs annually.7  
 
Chronic GVHD was first described in 1978 and has been defined as any 
alloimmunity that results in clinical manifestations that occur more 
than 100 days post HSCT.(2) Chronic GVHD occurs in 30 to 70% of 
patients who have undergone allogeneic HSCT of nonmanipulated donor 
grafts and have received standard prophylaxis with a calcineurin 
inhibitor and an antimetabolite.(1) Chronic GVHD can have protean 
manifestations that range from fibrotic skin disease resembling 
systemic sclerosis, bronchiolitis, salivary and lacrimal gland disease, 
and eosinophilic fasciitis.8  
 
The pathophysiology of chronic GVHD is believed to involve three 
phases: early inflammation and tissue injury, chronic inflammation and 
dysregulated immunity, and aberrant tissue repair often accompanied 
by fibrosis.(9) In the first phase, there is translocation of bacteria and 
fungi across epithelial tight junctions, which are believed to be made 
more porous as a result of tissue damage that may occur following 
cytotoxic cell conditioning with chemotherapy or radiotherapy during 
the process of HSCT. This porosity leads to the release of immunogenic 
molecules that are not normally found in the extracellular space, which 
triggers clonal expansion of B cells and differentiation of T cells into 
type 1, type 2, and type 17 helper T-cells. This expansion of T cells 
causes a concomitant increase in the amount of auto-reactive T cells 
that escape immune regulation both in the thymus and in the 
periphery. Autoreactive T cells, along with toxic effects of the 
conditioning regimen, prophylaxis with calcineurin inhibitors, and 
immunoglobulin deposition lead to further thymic injury which further 
degrades the immune system’s ability to filter out autoreactive immune 
cells in the thymus. In the final phase, activated macrophages secrete 
fibrotic growth factors such as Transforming Growth Factor Beta (TGF-
β) and Platelet-Derived Growth Factor (PDGF), which stimulate 
fibroblasts to lay down extracellular collagen and causes widespread 
fibrosis and sclerosis in various organs.1   
 
In 2005, the National Institutes of Health (NIH) compiled a formal set of 
guidelines regarding diagnosis of chronic GVHD, which were updated in 
2014, that stipulate that the diagnosis of chronic GVHD requires “at 
least 1 diagnostic manifestation of chronic GVHD or at least 1 distinctive 
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manifestation, with the diagnosis confirmed by pertinent biopsy, 
laboratory tests, or radiology in the same or another organ” along with 
distinction from acute GVHD and exclusion of other possible causes.4 
The mainstay of treatment of chronic GVHD requiring systemic 
treatment is and has been glucocorticoids, along with a calcineurin 
inhibitor. If patients require additional therapy following the prolonged 
use of glucocorticoids, secondary agents including rituximab, 
cyclophosphamide, imatinib, mycophenolate mofetil, IL-2, 
extracorporeal phonophoresis, methotrexate, bortezomib and as well 
as other novel immunosuppressive treatments are used.1,10  
 
Musculoskeletal manifestations that result from chronic GVHD are 
uncommon and likely to be missed by many clinicians who are unaware 
of this entity. The goal of reporting on the case below is to emphasize 
the importance of being aware of the presentation, diagnostic 
guidelines and recommended treatment of polymyositis secondary to 
chronic GVHD in patients who have undergone HSCT. 
 
The Case 
Here we report on the case of a 33-year-old male living in central Israel 
with a past medical history of Acute Myeloid Leukemia (AML) diagnosed 
two years prior who presented to his local hospital with a 1-month 
history of generalized weakness that was more pronounced in the 
lower body. The patient’s chief complaint was that he was having 
difficulty accomplishing tasks of daily living such as lifting items around 
the house, getting out of bed, preparing food and driving. He had 
initially gone to see a neurologist in his community, who noted that he 
had profound upper and lower body weakness and referred him to the 
local hospital. The patient stated that the weakness had begun to 
progress more rapidly in the 10 days leading up to his presentation and 
that he now needed to use crutches in order to walk. He reported no 
sensory deficits or urinary incontinence. He also denied a family history 
of neurological or musculoskeletal disease, significant history of 
substance abuse, recent notable travel or sick contacts or occupational 
exposures to toxic chemicals.   
 
The patient had been generally healthy prior to his diagnosis of AML 
two years prior. At that time, he had presented with complaints of 
fever, weakness, vertigo and headache for one week. Following an 
extensive work up, the patient was diagnosed with FMS-like tyrosine 
kinase 3-internal tandem duplication (FLT3-ITD) positive AML, which is 
named for its similarity to a tyrosine kinase that binds macrophage or 
monocyte colony-stimulating factor and is encoded by the Feline 
McDonough Sarcoma (FMS) oncogene.11 He was treated with a “7+3” 
regimen of daunorubicin and cytarabine plus midostaurine as well as 
prophylactic antibiotics and steroids. The patient ultimately underwent 
allogenic HSCT two months after his initial presentation with a donor 
who was a 10/10 match (both alleles matched at HLA loci A, B, C, DRB1, 
and DQB1). One month following his HSCT, the patient was hospitalized 
with a febrile illness and found to have elevated CMV titers as well as 
elevated AST and ALT enzymes. He was treated at the time for a 
suspected viral infection with valganciclovir, piperacillin/tazobactam 
and prednisone. The patient later developed facial skin rashes and oral 
ulcers and his prednisone dose was increased. Soon afterward, he also 
suffered from a febrile illness with respiratory symptoms including 
cough and slight oxygen desaturation. He underwent bronchoscopy and 
a biopsy was taken from his respiratory tract, which was later found to 
be positive for Corynebacterium and he was treated with antibiotics. 
Later that same year, the patient presented with a complaint of gross 
hematuria and he was again prescribed prednisone and the hematuria 
eventually resolved.   
 
At the patient’s presentation for a chief complaint of generalized 
weakness, he was taking voriconazole, acyclovir, and trimethoprim-
sulfamethoxazole for antibacterial and antiviral prophylaxis as well as 
sorafenib for maintenance AML treatment. He was tapering his dose of 
prednisone and currently taking 5mg daily, which was a decrease from 
60mg daily a few months prior. 
 
At the hospital, the patient’s vital signs showed that he was afebrile 
with a regular pulse of 85, a blood pressure of 107/55 and a respiratory 
rate within normal limits. The patient’s extraocular muscle movements 
and visual fields were intact. Both arms and legs were hypotonic and 
patient could not hold them up against gravity, however no pronation 
was noticed. Arm muscle strength was rated as 4+/5 bilaterally both 
proximal and distal. Wrist flexion was rated as 5/5. In the lower body, 
hip flexion was rated as 3/5 bilaterally, knee flexion was 4+/5 bilaterally, 
knee extension was 4+/5 bilaterally and foot plantar flexion and 
dorsiflexion was rated as 5/5 bilaterally. The patient’s reflexes were 2+ 
throughout without any pathological reflexes. Superficial touch was 
intact in upper and lower body. The patient’s gait was narrow-based 
with left foot dragging and he required a crutch in order to move around 
in his hospital room. 
 
Laboratory results showed that the patient had a macrocytic anemia of 
12.3 g/dL with a MCV of 99.4 (normal 80-94), thrombocytopenia of 90 
K/micl (normal 130-400), leukocytosis of 13.32 K/micl (normal 4.8-10.8) 
with eosinophilia of 4.3 K/micl (normal 0.0-0.8). All of these abnormal 
blood test findings were confirmed to have been noted on prior labs. 
The patient had CRP a 1.86 mg/L (normal 0.0 – 5.0) and ESR of 29 
(normal 0.0 – 8.0). Basic metabolic and coagulation panels were within 
normal limits. Patient’s CPK and TSH were within normal limits. A 
lumbar puncture was performed which revealed an opening pressure 
of 12 cm of H2O, 1 WBC/uL, no erythrocytes, glucose of 47 mg/dL and 
no xanthochromia. A flow cytometry test was negative for any abnormal 
cell populations in CSF and CSF culture and a Biofire panel for various 
microbiological pathogens was also negative. Patient serum and CSF 
was checked for antibodies including ANA, anti-dsDNA, anti-Jo1, anti-
Scl-70, anti-voltage-gated calcium channel, anti-acetylcholine receptor, 
anti-GM-1 among others and were all negative. Hepatitis and HIV tests 
were also negative. 
 
The patient was sent for a non-contrast head CT which showed a minor 
lesion in the right pons that was interpreted as an old finding that was 
likely an artifact. 
 
The patient was also sent for electromyography (EMG), which revealed 
no spontaneous activity upon needle insertion and low amplitude, 
polyphasic motor unit action potentials with decreased duration along 
with increased recruitment in all nerves including the median, ulnar, 
peroneal, tibial and axillary nerves. Nerve conduction studies showed 
distal motor latency and conduction velocity were preserved for both 
sensory and motor components. 
 
The patient was treated with 60mg of methylprednisolone IV and was 
referred to hematology for treatment of presumed polymyositis 
secondary to chronic GVHD. Muscle biopsy was also recommended in 
order to confirm the working diagnosis but deferred since it seemed 
reasonable to assume this was a manifestation of chronic GVHD given 
the patient’s history and findings. Following a stay in the hemato-
oncology department, the patient’s dose of steroids was changed to 
50mg daily of prednisone. The patient was instructed to continue taking 
prophylactic antibiotics and schedule a follow up appointment with his 
hematologist for continued treatment of chronic GVHD manifestations. 
 
Discussion 
This report details the case of a patient with a history of FLT3-ITD 
positive AML and acute and chronic GVHD who presented with 
progressive weakness of one month’s duration and was diagnosed with 
presumed polymyositis secondary to chronic GVHD. According to the 
NIH Consensus Criteria on Chronic GVHD, polymyositis is a recognized 
diagnostic finding in chronic GVHD (Figure 1) and, in this case, it was 
confirmed via EMG, which clearly demonstrated a myopathic pattern in 
multiple nerves in the upper and lower body. Other causes of myopathy 
including prolonged steroid use, auto-immune disease, hypokalemia, 
hypothyroidism, infection and otherwise were ruled out and the 
patient’s presentation timeframe of more than 100 days post HSCT 
excluded acute GVHD as a potential cause. 
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Musculoskeletal manifestations of chronic GVHD are very rare and when 
present do not usually manifest as myositis. In a retrospective chart 
review of all cases of myositis that developed in 7161 patients who 
underwent HSCT at the Fred Hutchinson Cancer Research Center in 
Seattle, Washington between 1969 and 1999, only 12 patients out of 
1859 (0.6%) who developed chronic GVHD also developed myositis 
between 7 and 55 months after HSCT.12 In another case series of 381 
patients with chronic GVHD, Parker at el. reported that myositis 
occurred in 11 patients out of 318 (3.5%).13 The incidence of myositis in 
the first study at the Hutchinson Cancer Center was calculated to be 23 
per 100,000 person-years for all HSCT patients and 49 per 100,000 
person-years for HSCT patients who had previously reported chronic 
GVHD manifestations.12 For a comparison of prevalence in the general 
population, in a large study that looked at 35 million commercially 
insured individuals in the US, the incidence of idiopathic inflammatory 
myositis (including dermatomyositis, polymyositis and sporadic 
inclusion body myositis), was found to be between 5.8 to 7.9 per 
100,000 person-years from 2003-2008.14  
 
 
 
Figure 1. Section of Scoring Card from NIH Chronic Graft Versus Host Disease Criteria Relevant to Musculoskeletal Manifestations. 
 
 
Legend. Section of organ system scoring card relevant to musculoskeletal complications of chronic GVHD as drafted by The National Institutes of Health Consensus Development 
Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease in 2014. The scoring card focuses mostly on musculoskeletal changes related to joint contractures, 
fasciitis and their related manifestations with a photographic range of motion scale provided for ranking perceived joint range of motion. There is also a box that can be ticked 
with a related severity scale of 1-3 in case of noted polymyositis.15 
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In patients who do develop musculoskeletal complications of chronic 
GVHD, the most common manifestation is fasciitis that is characterized 
by sclerosis of the overlying skin and subcutaneous tissues causing 
joint contractures, edema and restricted range of motion.15 Figure 1 
shows the section of the scoring card that is pertinent to 
musculoskeletal manifestations provided by the National Institutes of 
Health to rate the severity of chronic GVHD. In that section, a scoring 
system is shown that allows clinicians to rate the severity of joint 
contractures and to tick a box if polymyositis, peripheral neuropathy 
and/or myasthenia gravis are present and, if so, to indicate the degree 
of severity. Besides evaluating for joint contractures, clinicians caring 
for patients with musculoskeletal symptoms of chronic GVHD should 
always monitor a patient’s respiratory rate and oxygen saturation since 
there are reports of respiratory failure as a result of weakness of the 
respiratory muscles in chronic GVHD.16  
 
Another etiology of myositis that was considered in this patient was 
medication-induced myositis. The patient has been regularly taking 
sorafenib, a tyrosine kinase inhibitor that has been shown to increase 
event-free survival in patients younger than 60 years old with FLT3-ITD 
positive AML albeit with increased toxicity.17 While Sorafenib has been 
reported to cause myositis in at least one case report, however it was 
not believed to be the culprit in this patient’s case since the patient 
had been taking the drug for several months before the onset of 
weakness and myopathic symptoms appear to be a relatively rare side 
effect.18 As a result, the patient was instructed to continue taking 
sorafenib as maintenance for AML.  
 
This patient presented with normal levels of CPK, which may make this 
presentation unusual since in one review of 36 cases of polymyositis 
due chronic GVHD, it was reported that the majority of patients 
presented with elevated CPK and aldolase levels.19 Aldolase was not 
measured in this patient, so unfortunately we cannot know if it was 
elevated or not. As for the normal level of CPK, while this enzyme 
typically parallels disease activity in most patients with myositis, it may 
be normal or only slightly elevated in different types of myositis.20 This 
patient did have a history of acute GVHD, which may or may not be 
present in common presentations of this disease. In the same case 
series that reported data on elevated CPK, Couriel et al. found that 
about half of the patients did not have any history of an episode of 
acute GVHD prior to their presentation with symptoms of polymyositis.19 
This also means that a significant percentage of patients are likely to 
present with myositis without any prior indications of graft-versus-host 
disease. 
 
In muscle biopsies taken in cases of myositis secondary to chronic 
GVHD, one should expect the same findings as in idiopathic 
polymyositis, namely perimysial and endomysial infiltrate of CD4+ and 
CD8+ T cells in the myofibrils.19 This is confirmed in a report by 
Takahashi et al., who reported CD4+ and CD8+ T cells in the perimysial 
infiltrate and primarily CD8+ infiltrate in the endomysial layer in a 22-
year-old patient with polymyositis secondary to chronic GVHD.21 
Examples of pathology slides showing expected findings can be seen 
in Figure 2 and Figure 3. 
 
This case shows that it is important for clinicians to be familiar with 
the phenomenon of polymyositis as a manifestation of chronic GVHD, 
especially since the etiology of myopathy in these patients may easily 
be mistaken for something else since they often suffer from multiple 
co-morbidities and are often on immunosuppressive therapy as well as 
other medications. Furthermore, more research is necessary to find 
more effective prophylactic and therapeutic treatments for chronic 
GVHD that possess a lighter side effect burden with long-term use. 
Current directions of investigation, which include impeding B cell 
signaling and germinal center formation, increasing regulatory T cells 
populations, targeting pro-fibrotic interleukins and T and B cell 
recruiting chemokines have shown some promise but require more 
patients and clinical trials to be further validated.1 
Figure 2. Lymphocytic Infiltrate in Muscle Tissue. 
 
 
 
Legend; An H&E section of a muscle tissue showing infiltration of lymphocytes as well 
as myopathic features including smaller, rounded myofibers with increased internal 
nuclei. Courtesy of Meggen Walsh, D.O., M.S.-P.A.22 
 
Figure 3. CD8+ T Cell Infiltrate in Muscle Tissue 
 
 
 
Legend: Immunostaining of muscle from H&E section showing that infiltrate is 
composed of CD3+ CD8+ T cells. Courtesy of Meggen Walsh, D.O., M.S.-P.A.22
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